Kartos Therapeutics
Tracked across 3 events · 20 articles · First seen Apr 20, 2026 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Kartos Therapeutics is being acquired by Ipsen for up to $1.75 billion, including an upfront payment and potential milestone payments. Its primary asset, navtemadlin, will be integrated into Ipsen's pipeline.
Apr 20, 2026 · 7 articles
Business
Ipsen announced on 21 August 2026 that it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. The acquisition adds navtemadlin, a late-stage MDM2 inhibitor in Phase III development for myelofibrosis, to Ipsen's…
Impact: Kartos Therapeutics was acquired by Ipsen, providing shareholders with a $450 million upfront payment and potential milestones. The acquisition validates its lead asset navtemadlin.
Aug 21, 2026 · 7 articles
Business
Impact: Kartos Therapeutics is mentioned as a current board seat for Borellini; not directly affected by this event.
Jul 13, 2026 · 6 articles
100
Ipsen acquired Kartos TherapeuticsIpsen completes Kartos...
ERGEN INTELLIGENCE
Track Kartos Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard